Why Is SELLAS LIFE SCIENCES (SLS) Stock Moving Today?

SLS stock is moving amid speculation about potential biotech buyouts involving Merck’s Keytruda, as retail traders compare SELLAS Life Sciences with Myriad Genetics. The stock has declined 14.4% over the last eight sessions, falling from $14.76 to $12.64. The recent coverage highlights SLS’s momentum in this competitive landscape, even as MLTX is seen as a more affordable and better-capitalized alternative.

What Happened

According to Stocktwits News, SLS is being positioned as a contender in the race for Merck’s next biotech acquisition as Keytruda approaches its $31.7 billion patent cliff. The report notes that SLS leads in stock momentum, while MLTX holds a financial edge with nearly $300 million in cash as of the end of the first quarter. This comparison is driving retail trader interest, with investors weighing which biotech could be the next target for Merck’s expansion strategy. The average AI sentiment for the headline is 56 out of 100, slightly above neutral.

What The Data Shows

The stock has seen a significant price drop over the past eight trading sessions, declining 14.4% to $12.64 from $14.76. Meanwhile, Reddit mentions for SLS have been minimal in the last seven days, with only one post recorded and an average sentiment score of 50, indicating neutrality. These figures suggest limited retail buzz beyond the recent Stocktwits report.

What To Watch

Traders should continue monitoring the broader coverage and sentiment around biotech acquisition speculation, particularly as Keytruda’s patent expiration looms. The momentum and positioning of SLS versus MLTX may shift based on further developments in the sector.